Richard Philipson appointed as chief medical officer of Hansa Biopharma

Ella Day | July 9, 2025 | Appointment | Research and Development |  Hansa Biopharma, Immunology, chief medical officer, immunology 

Hansa Biopharma has announced that Richard Philipson has been appointed chief medical officer, effective 14 July. Philipson will join the executive committee and will report to recently appointed CEO, Renée Aguiar-Lucander.

Philipson brings over 25 years of experience across numerous phases of clinical development, including regulatory strategy, budgetary management and developing treatments for rare diseases. Most recently, he was CMO of Calliditas Therapeutics. Prior to that, he spent 16 years at GlaxoSmithKline in a number of leadership positions including director of clinical development and therapeutic area head in the company’s rare diseases unit. He has also previously worked at Takeda and spent four years as CMO at Trizell.  

“We are very pleased to welcome Philipson,” said CEO Renée Aguiar-Lucander. “He brings invaluable experience in the area of drug development, from first-in-human to phase 3, and post-approval studies; with expertise across rare diseases, inflammation and oncology, which will be critical as we prepare for the next phase of our development.”

Philipson added: “I am excited to have the opportunity to join Hansa at this stage of the company’s development (…) and help build a strategic development plan for future indications.”

Hansa focuses on developing treatments for rare immunological conditions. Its portfolio includes imlifidase, an immunoglobulin G antibody-cleaving enzyme therapy, shown to enable kidney transplantation in highly-sensitised patients.

Ella Day

9/7/25